Drugs / VRC-CHKVLP059-00-VP
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03028441 | May 2017 → Jan 2019 | chikungunya | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01489358 | Dec 2011 → Apr 2013 | chikungunya | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02562482 | Nov 2015 → Mar 2018 | chikungunya | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-CHKVLP059-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03028441 ↗ |
| Known as | MV-CHIK | “Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK)” NCT03028441 ↗ |
| Modality | Vaccine | “a virus-like particle (VLP) chikungunya virus vaccine, VRC-CHKVLP059-00-VP” PMID 25132507 ↗ Aug 2014 |
| Route | Intramuscular | “The plan is for 25 subjects to receive 3 intramuscular vaccine injections at weeks 0, 4, and 20.” NCT01489358 ↗ |